AATEC MEDICAL SECURES FOUR MILLION FOR ENTRY INTO CLINICAL TRIALS
Funding from SPRIND and family offices accelerates preparation of the drug candidate ATL-105 for the treatment of respiratory diseases
AATec Medical GmbH (AATec), a biotech company developing a multi-product platform for the treatment of respiratory diseases based on recombinant alpha-1 antitrypsin (AAT), today announced that it has secured EUR four million in a pre-series A financing from Germany’s Federal Agency for Breakthrough Innovation (SPRIND) and high-net worth individuals investors, industry experts and single family offices.
The proceeds will be used to advance the development of ATL-105, AATec’s lead drug candidate in chronic respiratory inflammation and infectious respiratory diseases. ATL-105 will initially be developed for the treatment of non-cystic fibrosis bronchiectasis (NCFB), a chronic inflammatory respiratory disease without any causative therapies. Current NCFB treatment is limited to symptomatic therapy including antibiotics, macrolides, and physical therapy. The funding will support IND-enabling activities and position ATL-105 for entry into clinical trials by 2026.
Dr. Rüdiger Jankowsky, co-founder and CEO of AATec, commented: This funding is a crucial step toward preparing ATL-105 for clinical development. Non-CF bronchiectasis significantly impacts patients' quality of life, and current treatment options are limited. We believe that ATL-105 has the potential to offer a meaningful therapeutic advance for millions of patients worldwide. In Western countries alone, more than 3 million patients suffer from NCFB. Thanks to our novel protein inhalation approach, ATL-105 is delivered directly to the lungs, maximizing therapeutic effectiveness at the primary site of inflammation and minimizing systemic side effects. The support from SPRIND validates our innovative approach and highlights the transformative potential of our technology.
Sigrid Koeth, Innovation Manager at SPRIND, added: At SPRIND, we're looking for ideas that can fundamentally change things for the better. We believe that AATec’s approach using recombinant alpha-1 antitrypsin has great potential in a wide range of respiratory diseases and infections. Innovations like this can be key in protecting public health and strengthening the resilience of our healthcare systems.
AATec Medical’s lead product candidate, ATL-105, is based on a novel recombinant alpha-1 antitrypsin (AAT), a human serine protease inhibitor with broad anti-inflammatory, immunomodulatory and anti-infective properties. Robust preclinical proof-of-principle data demonstrate ATL-105’s excellent safety profile and broad therapeutic potential by effectively targeting key pathological processes in inflammatory lung diseases.
ABOUT AATEC MEDICAL
AATec Medical GmbH is a biotechnology company developing a product platform based on recombinant alpha-1 antitrypsin (AAT) for the treatment of respiratory inflammatory diseases, airway infections and rare diseases. The company has successfully demonstrated proof-of-principle in several indications and is currently preparing for a proof-of-concept clinical trial with the first product candidate ATL-105 for inhaled application in non-CF bronchiectasis. AATec was founded by a seasoned interdisciplinary team with long-standing experience in clinical research, biopharmaceutical development and product industrialization.
